Shelter-at-home restrictions affected demand for Opdivo in the first half of fiscal 2020, but the fundamentals behind the drug haven't changed. Demand for Opdivo as a second-line treatment option for non-small cell lung cancer (NSCLC) remains stable, and the combination therapy of Opdivo plus another Bristol Myers Squibb drug, Yervoy, is a leader in treating renal cell carcinoma. For these reasons, the company expects Opdivo to return to annual revenue growth in fiscal 2021.